Exhibit 99.1
|
|
|
|
|
|
|
|
|
Press Release - Regulated Information |
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Mont-Saint-Guibert, Belgium, December 15, 2023, 10:01 pm CET; regulated information Celyad Oncology (Euronext: CYAD)
(the Company or Celyad Oncology), today announces that 6,500,000 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of December 8, 2023. As a result, the Companys total number of voting rights
is now 50,296,947.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major
participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures Modified
on December 8, 2023, following the Double Voting Right:
|
|
|
|
|
Total amount of share capital (EUR) |
|
|
88,378,224.25 |
|
Total Number of shares with single voting rights |
|
|
32,560,197 |
|
Total Number of shares with double voting rights |
|
|
8,868,375 |
|
Total Number of Shares |
|
|
41,428,572 |
|
Total of voting rights |
|
|
50,296,947 |
|
Total number of attributed warrants |
|
|
3,038,871 |
|
Total number of shares with voting rights that could be created following the exercise of the
attributed warrants |
|
|
3,038,871 |
|
Total number of diluted shares (Outstanding shares + Warrants) |
|
|
44,457,443 |
|
Total number of diluted voting rights |
|
|
53,335,818 |
|
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Michel Lussier, Chief Executive Officer ad interim (CEO ad
interim): investors@celyad.com.
Further questions about the content of this release can be sent to investors@celyad.com.
About Celyad Oncology
Celyad Oncology is a cutting-edge
biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its
proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad
Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in
Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
Forward-looking statements
This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act
of 1995, as amended, including, without limitation, statements regarding beliefs about and expectations for the Companys updated strategic business model, including associated potential benefits, transactions and partnerships, statements
regarding the potential value of the Companys IP, and statements regarding the continuation of the Companys existence. The
Page 1 of 2